Metabolic Dysfunction-Associated Steatotic Liver Disease: From NAFLD to MASLD: Implications of the New Nomenclature for Clinical Practice

Author(s)	Dr. Mohammed Khaja Moinudeen, Ms. Preety Sen, Ms. Srishti Baruah, Mr. Dhruv Guru Prasad, Mr. Kartik Khetade
Country	India
Abstract	The transition from Non-Alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) marks a pivotal shift in hepatology. This new nomenclature, endorsed by major international societies in 2023, emphasizes the metabolic roots of the condition while reducing stigma. It moves away from exclusionary language toward a positive, etiology-focused diagnosis. This paper explores the rationale behind the change, its diagnostic and therapeutic implications, and how clinicians can integrate it into everyday practice. With MASLD affecting over a third of adults globally and rising rapidly alongside obesity and diabetes, embracing this framework could improve early detection, patient engagement, and multidisciplinary care — ultimately curbing the tide of liver-related complications.
Field	Medical / Pharmacy
Published In	Volume 8, Issue 4, July-August 2026
Published On	2026-07-06

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9687-828-838	editor@ijfmr.com

International Journal For Multidisciplinary Research